Symptoms of overdose include darkening of skin, drowsiness or tiredness, loss of appetite, mental depression, skin rash, and/or vomiting.
Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Trilostane. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Trilostane. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Trilostane. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Trilostane. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Trilostane. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Trilostane. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Trilostane. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trilostane. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trilostane. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trilostane. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trilostane. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Trilostane. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Trilostane. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Trilostane. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trilostane. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Trilostane. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trilostane. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Trilostane. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Trilostane. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trilostane. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trilostane. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Trilostane. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trilostane. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Trilostane. |
| Cladribine | Trilostane may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Trilostane. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Trilostane. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Trilostane. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Trilostane. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Trilostane. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Trilostane. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Trilostane. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Trilostane. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Trilostane. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Trilostane. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trilostane. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Trilostane. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Trilostane. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Trilostane. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Trilostane. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Trilostane. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Trilostane. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Trilostane. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Trilostane. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Trilostane. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Trilostane. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Trilostane. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Trilostane. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Trilostane. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Trilostane. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Trilostane. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Trilostane. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Trilostane. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Trilostane. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Trilostane. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Trilostane. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Trilostane. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Trilostane. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Trilostane. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Trilostane. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Trilostane. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Trilostane. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Trilostane. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Trilostane. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Trilostane. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Trilostane. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Trilostane. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Trilostane. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Trilostane. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Trilostane. |
| Procarbazine | The risk or severity of adverse effects can be increased when Trilostane is combined with Procarbazine. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Trilostane is combined with Arsenic trioxide. |
| Idarubicin | The risk or severity of adverse effects can be increased when Trilostane is combined with Idarubicin. |
| Estramustine | The risk or severity of adverse effects can be increased when Trilostane is combined with Estramustine. |
| Lomustine | The risk or severity of adverse effects can be increased when Trilostane is combined with Lomustine. |
| Eculizumab | The risk or severity of adverse effects can be increased when Trilostane is combined with Eculizumab. |
| Decitabine | The risk or severity of adverse effects can be increased when Trilostane is combined with Decitabine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Trilostane. |
| Stepronin | The risk or severity of adverse effects can be increased when Trilostane is combined with Stepronin. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Trilostane is combined with Hydroxychloroquine. |
| Castanospermine | The risk or severity of adverse effects can be increased when Trilostane is combined with Castanospermine. |
| Vorinostat | The risk or severity of adverse effects can be increased when Trilostane is combined with Vorinostat. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when Trilostane is combined with 2-Methoxyethanol. |
| Brequinar | The risk or severity of adverse effects can be increased when Trilostane is combined with Brequinar. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Trilostane is combined with Pirfenidone. |
| Belinostat | The risk or severity of adverse effects can be increased when Trilostane is combined with Belinostat. |
| Trabectedin | The risk or severity of adverse effects can be increased when Trilostane is combined with Trabectedin. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Trilostane is combined with Interferon alfa. |
| Glatiramer | The risk or severity of adverse effects can be increased when Trilostane is combined with Glatiramer. |
| Briakinumab | The risk or severity of adverse effects can be increased when Trilostane is combined with Briakinumab. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Trilostane is combined with Human interferon omega-1. |
| Panobinostat | The risk or severity of adverse effects can be increased when Trilostane is combined with Panobinostat. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Trilostane is combined with Mepolizumab. |
| Abetimus | The risk or severity of adverse effects can be increased when Trilostane is combined with Abetimus. |
| Belatacept | The risk or severity of adverse effects can be increased when Trilostane is combined with Belatacept. |
| Bendamustine | The risk or severity of adverse effects can be increased when Trilostane is combined with Bendamustine. |
| Cabazitaxel | The risk or severity of adverse effects can be increased when Trilostane is combined with Cabazitaxel. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Trilostane is combined with Pralatrexate. |
| Wortmannin | The risk or severity of adverse effects can be increased when Trilostane is combined with Wortmannin. |
| Eribulin | The risk or severity of adverse effects can be increased when Trilostane is combined with Eribulin. |